DexCom (DXCM) Set to Announce Quarterly Earnings on Thursday

DexCom (NASDAQ:DXCM) is set to issue its quarterly earnings data after the market closes on Thursday, April 25th. Analysts expect the company to announce earnings of $0.27 per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, February 8th. The medical device company reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.07. The business had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $1.02 billion. DexCom had a net margin of 14.95% and a return on equity of 28.31%. The business’s revenue for the quarter was up 26.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.34 EPS. On average, analysts expect DexCom to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

DexCom Price Performance

DXCM opened at $134.00 on Wednesday. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.48 and a current ratio of 2.84. The stock has a market capitalization of $51.66 billion, a P/E ratio of 102.29, a P/E/G ratio of 2.25 and a beta of 1.20. The company’s 50-day simple moving average is $130.15 and its two-hundred day simple moving average is $117.74. DexCom has a 52-week low of $74.75 and a 52-week high of $142.00.

Analyst Upgrades and Downgrades

DXCM has been the topic of several research analyst reports. Raymond James upped their target price on shares of DexCom from $147.00 to $151.00 and gave the company a “strong-buy” rating in a research note on Tuesday, January 23rd. Citigroup upped their target price on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Royal Bank of Canada initiated coverage on shares of DexCom in a research report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price target for the company. StockNews.com lowered shares of DexCom from a “buy” rating to a “hold” rating in a research report on Tuesday. Finally, UBS Group upped their price target on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. Three equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $141.40.

Insider Buying and Selling

In related news, EVP Matthew Vincent Dolan sold 1,990 shares of the stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $137.81, for a total value of $274,241.90. Following the completion of the sale, the executive vice president now directly owns 42,377 shares of the company’s stock, valued at approximately $5,839,974.37. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, EVP Matthew Vincent Dolan sold 1,990 shares of the stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $137.81, for a total value of $274,241.90. Following the completion of the sale, the executive vice president now directly owns 42,377 shares of the company’s stock, valued at approximately $5,839,974.37. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Jereme M. Sylvain sold 3,363 shares of DexCom stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $116.73, for a total transaction of $392,562.99. Following the sale, the chief financial officer now owns 71,142 shares in the company, valued at approximately $8,304,405.66. The disclosure for this sale can be found here. In the last ninety days, insiders sold 189,375 shares of company stock valued at $25,530,859. 0.41% of the stock is owned by corporate insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.